MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony diagnostycznie zaawansowany lub przerzutowy nowotwór z mierzalną chorobą
- •Posiadanie mutacji KRAS G12D w komórkach raka lub we krwi
- •Dobre ogólne samopoczucie pozwalające na aktywność (status wydolności ≤1)
- •Co najmniej jedno wcześniejsze leczenie chemioterapią z powodu zaawansowanego raka
- •Przerzuty do mózgu mogą być dopuszczalne, jeśli nie powodują objawów lub są leczone
✗ Disqualifies
- •Aktywne przerzuty do mózgu powodujące objawy
- •Nieustąpione efekty uboczne z poprzedniego leczenia powyżej stopnia 1
- •Poważne choroby serca, w tym zawały w przeszłości lub zaburzenia funkcji serca
- •Aktywna, niekontrolowana infekcja (bakteryjna, wirusowa, grzybiczna)
- •Aktywne wirusowe zapalenie wątroby (HBV lub HCV)
- •Inny aktywny nowotwór, chyba że jest w remisji z oczekiwaną przeżywalnością powyżej 2 lat
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 24, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (52)
City of Hope
Duarte, United States
University of California, Los Angeles (UCLA)
Santa Monica, United States
Sarah Cannon Research Institute at HealthOne
Denver, United States
Sibley Memorial Hospital
Washington D.C., United States
Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute
Orlando, United States
Emory University School of Medicine
Atlanta, United States
Community Health Network
Indianapolis, United States
Massachusetts General Hospital
Boston, United States
Dana-Farber Cancer Institute
Boston, United States
Barbara Ann Karmanos Cancer Institute
Detroit, United States
South Texas Accelerated Research Therapeutics (START) Midwest
Grand Rapids, United States
New York University (NYU) Langone Medical Center
New York, United States
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, United States
Duke University Medical Center
Durham, United States
University of Cincinnati (UC) - Cancer Institute
Cincinnati, United States
Cleveland Clinic
Cleveland, United States
University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center
Pittsburgh, United States
Sarah Cannon Research Institute
Nashville, United States
USO - US Oncology Research Network
Nashville, United States
Vanderbilt University School of Medicine
Nashville, United States
MD Anderson Cancer Center
Houston, United States
South Texas Accelerated Research Therapeutics (START)
San Antonio, United States
Huntsman Cancer Institute
Salt Lake City, United States
Fred Hutchinson Cancer Center
Seattle, United States
University of Wisconsin - Carbone Cancer Center
Madison, United States
The Ottawa Hospital
Ottawa, Canada
Princess Margaret Hospital
Toronto, Canada
Cancer Institute & Hospital, Chinese Academy of Medical Sciences
Beijing, China
Beijing Cancer hospital
Beijing, China
Harbin Medical University Cancer Hospital
Harbin, China
Fudan University Shanghai Cancer Center
Shanghai, China
Centre Leon Berard
Lyon, France
Centre d'Essais Precoces en Cancerologie de Marseille (CEPCM) - AP-HM Hopital de La Timone
Marseille, France
Oncopole Claudius Regaud
Toulouse, France
Institut Gustave Roussy
Villejuif, France
Charite Universitaetsmedizin Berlin
Berlin, Germany
Universitaetsklinikum Carl Gustav Carus Dresden
Dresden, Germany
Universitaetsklinikum Essen
Essen, Germany
Klinikum der Ludwig-Maximilians-Universitaet Muenchen
München, Germany
START Dublin Early Phase Clinical Trials Unit
Dublin, Ireland
Azienda Ospedaliera Universitaria - Universita degli Studi della Campania Luigi Vanvitelli
Naples, Italy
UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
Roma, Italy
Centro Ricerche Cliniche di Verona s.r.l.
Verona, Italy
National Cancer Center Hospital East
Chiba, Japan
Kanagawa cancer center
Kanagawa, Japan
Aichi Cancer Center Hospital
Nagoya, Japan
Kansai Medical University Hospital
Osaka, Japan
National Cancer Center Hospital
Tokyo, Japan
South Texas Accelerated Research Therapeutics (START) Barcelona- HM Nou Delfos
Barcelona, Spain
Hospital Universitario Vall d'Hebron
Barcelona, Spain
South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Trial contact
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Physicians interested in becoming principal investigators please contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/25/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.